2013
Morphine dependence and withdrawal induced changes in cholinergic signaling
Neugebauer NM, Einstein EB, Lopez MB, McClure-Begley TD, Mineur YS, Picciotto MR. Morphine dependence and withdrawal induced changes in cholinergic signaling. Pharmacology Biochemistry And Behavior 2013, 109: 77-83. PMID: 23651795, PMCID: PMC3690589, DOI: 10.1016/j.pbb.2013.04.015.Peer-Reviewed Original ResearchConceptsMedial habenulaMorphine dependenceCholinergic signalingInterpeduncular nucleusHigh-affinity nicotinic acetylcholine receptorsNicotinic acetylcholine receptor levelsEffects of cholinergicMorphine-dependent miceChronic morphine administrationAcetylcholine receptor levelsC-fos expressionC-Fos activationNicotinic acetylcholine receptorsDependent miceMorphine administrationMorphine withdrawalCholinergic drugsOpiate withdrawalCholinergic systemEpibatidine bindingReceptor levelsSomatic signsNeuronal activityAcetylcholine receptorsNAChR receptor
2011
Galanin negatively modulates opiate withdrawal via galanin receptor 1
Holmes FE, Armenaki A, Iismaa TP, Einstein EB, Shine J, Picciotto MR, Wynick D, Zachariou V. Galanin negatively modulates opiate withdrawal via galanin receptor 1. Psychopharmacology 2011, 220: 619-625. PMID: 21969124, PMCID: PMC3324978, DOI: 10.1007/s00213-011-2515-x.Peer-Reviewed Original ResearchConceptsGalanin receptor 1Chronic morphine administrationMorphine administrationLocus coeruleusGalanin expressionOpiate withdrawalReceptor 1Distinct G protein-coupled receptorsPrecipitation of withdrawalAction of morphineDoses of morphineWild-type miceTransgenic mouse lineG protein-coupled receptorsExpress galaninGalanin levelsWild-type controlsProtein-coupled receptorsNeuropeptide galaninMorphine dependenceWithdrawal signsOpiate dependenceGalaninTransgenic miceGalR2 gene
2006
Galanin: a novel therapeutic target for depression, anxiety disorders and drug addiction?
Holmes A, Picciotto MR. Galanin: a novel therapeutic target for depression, anxiety disorders and drug addiction? CNS & Neurological Disorders - Drug Targets 2006, 5: 225-32. PMID: 16611095, DOI: 10.2174/187152706776359600.Peer-Reviewed Original ResearchConceptsStress-related neural pathwaysBrain stress pathwaysSerotonin-producing neuronsDistribution of galaninDepression-related behaviorsDorsal raphe nucleusExpression of galaninAdministration of galaninNovel therapeutic targetDrug addictionPotential roleAnxiety-like responsesGalanin agonistsGalanin systemRaphe nucleusDopamine neuronsOpiate withdrawalLocus coeruleusNeuronal typesRodent modelsCurrent evidenceGalaninPsychiatric disordersTherapeutic targetOpiate reinforcementGalanin attenuates cyclic AMP regulatory element‐binding protein (CREB) phosphorylation induced by chronic morphine and naloxone challenge in Cath.a cells and primary striatal cultures
Hawes JJ, Narasimhaiah R, Picciotto MR. Galanin attenuates cyclic AMP regulatory element‐binding protein (CREB) phosphorylation induced by chronic morphine and naloxone challenge in Cath.a cells and primary striatal cultures. Journal Of Neurochemistry 2006, 96: 1160-1168. PMID: 16417577, DOI: 10.1111/j.1471-4159.2005.03613.x.Peer-Reviewed Original ResearchConceptsOpiate withdrawalAdditional potential therapeutic targetsChronic opiate administrationPotential therapeutic targetPrimary striatal culturesExtracellular signal-regulated kinase 1/2 phosphorylationElement-Binding Protein PhosphorylationCAMP regulatory element-binding proteinKinase 1/2 phosphorylationGalanin treatmentMorphine administrationChronic morphineGalanin receptorsNeuropeptide galaninOpiate administrationNaloxone challengeStriatal neuronsLocus coeruleusSomatic signsNucleus accumbensStriatal culturesRegulatory element-binding proteinTherapeutic targetElement-binding proteinMolecular alterations
2004
Characterization of GalR1, GalR2, and GalR3 immunoreactivity in catecholaminergic nuclei of the mouse brain
Hawes JJ, Picciotto MR. Characterization of GalR1, GalR2, and GalR3 immunoreactivity in catecholaminergic nuclei of the mouse brain. The Journal Of Comparative Neurology 2004, 479: 410-423. PMID: 15514977, DOI: 10.1002/cne.20329.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBrainCatecholaminesGalaninImmunohistochemistryLocus CoeruleusMiceNeural PathwaysNeuronsNucleus AccumbensOpioid-Related DisordersReceptor, Galanin, Type 1Receptor, Galanin, Type 2Receptor, Galanin, Type 3Receptors, GalaninRewardSubstantia NigraTyrosine 3-MonooxygenaseVentral Tegmental AreaConceptsVentral tegmental areaSubstantia nigraLocus coeruleusNucleus accumbensGalanin receptorsBrain areasMouse brainDistribution of immunoreactivityNoradrenergic transmissionGalanin bindingOpiate withdrawalTegmental areaCatecholaminergic nucleiTyrosine hydroxylaseDopamine neurotransmissionGalR1GalR2GalR3BrainProtein levelsDrug addictionGalaninImmunoreactivityReceptorsCoeruleus
2003
The neuropeptide galanin modulates behavioral and neurochemical signs of opiate withdrawal
Zachariou V, Brunzell DH, Hawes J, Stedman DR, Bartfai T, Steiner RA, Wynick D, Langel Ü, Picciotto MR. The neuropeptide galanin modulates behavioral and neurochemical signs of opiate withdrawal. Proceedings Of The National Academy Of Sciences Of The United States Of America 2003, 100: 9028-9033. PMID: 12853567, PMCID: PMC166432, DOI: 10.1073/pnas.1533224100.Peer-Reviewed Original ResearchConceptsMorphine withdrawal signsWithdrawal signsOpiate withdrawalGalanin agonistsEffects of galaninLocus coeruleus neuronsC-Fos immunoreactivityBlood-brain barrierEndogenous galaninMorphine withdrawalNoradrenergic neuronsCoeruleus neuronsC57BL/6 miceNeurochemical signsNeuropeptide galaninLocus coeruleusPossible molecular mechanismsTyrosine hydroxylaseGalaninNeuronal activityGalanin peptidePhysical signsTransgenic miceDrug dependenceBehavioral effects
2001
Galanin receptor 1 gene expression is regulated by cyclic AMP through a CREB‐dependent mechanism
Zachariou V, Georgescu D, Kansal L, Merriam P, Picciotto M. Galanin receptor 1 gene expression is regulated by cyclic AMP through a CREB‐dependent mechanism. Journal Of Neurochemistry 2001, 76: 191-200. PMID: 11145992, DOI: 10.1046/j.1471-4159.2001.00018.x.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBase SequenceCell LineCloning, MolecularCodon, InitiatorColforsinCyclic AMPCyclic AMP Response Element-Binding ProteinGene Expression RegulationMiceMolecular Sequence DataMutagenesis, Site-DirectedNerve Growth FactorNeuronsPromoter Regions, GeneticReceptors, GalaninReceptors, NeuropeptideRegulatory Sequences, Nucleic AcidSequence Homology, Nucleic AcidTetradecanoylphorbol AcetateTransfectionConceptsLocus coeruleusOpiate withdrawalGalanin binding sitesPeripheral nervous systemCREB-dependent mechanismG protein-coupled receptorsLevels of cAMPProtein-coupled receptorsOpiate analgesiaNeuropeptide galaninGalanin receptorsGalR1 mRNANervous systemPlace preferenceTranscription factor CREBForskolin effectGALR1 expressionGalR1 geneCAMP levelsCyclic AMPCell linesBasal activityCRE-like siteTransient transfection assaysReceptors
2000
Upregulation of Galanin Binding Sites and GalR1 mRNA Levels in the Mouse Locus Coeruleus Following Chronic Morphine Treatments and Precipitated Morphine Withdrawal
Zachariou V, Thome J, Parikh K, Picciotto M. Upregulation of Galanin Binding Sites and GalR1 mRNA Levels in the Mouse Locus Coeruleus Following Chronic Morphine Treatments and Precipitated Morphine Withdrawal. Neuropsychopharmacology 2000, 23: 127-137. PMID: 10882839, DOI: 10.1016/s0893-133x(00)00094-4.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAutoradiographyBehavior, AnimalDrug Administration ScheduleFemaleGalaninIn Situ HybridizationIodine RadioisotopesLocus CoeruleusMiceMice, Inbred C57BLMorphineNaltrexoneNucleus AccumbensReceptors, GalaninReceptors, NeuropeptideRNA, MessengerSubstance Withdrawal SyndromeUp-RegulationVentral Tegmental AreaConceptsGalanin binding sitesLocus coeruleusMorphine treatmentMRNA levelsAcute morphine treatmentChronic morphine treatmentMouse locus coeruleusReceptor 1 geneLC neuronsMorphine administrationMorphine withdrawalNeuropeptide galaninOpiate withdrawalReceptor levelsBrain areasDrug dependenceGalaninCAMP levelsWithdrawalBinding sitesCoeruleusTreatmentLevelsGalR1Neurons